Summary
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
According to APO Research, The global PD-L1 and PIK3CA Testing market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PD-L1 and PIK3CA Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for PD-L1 and PIK3CA Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for PD-L1 and PIK3CA Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for PD-L1 and PIK3CA Testing is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of PD-L1 and PIK3CA Testing include Agilent Technologies, Roche, QIAGEN, EntroGen, Amoy Diagnostics and ACCB Biotech, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for PD-L1 and PIK3CA Testing, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of PD-L1 and PIK3CA Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for PD-L1 and PIK3CA Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-L1 and PIK3CA Testing revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global PD-L1 and PIK3CA Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for PD-L1 and PIK3CA Testing revenue, projected growth trends, production technology, application and end-user industry.
PD-L1 and PIK3CA Testing segment by Company
Agilent Technologies
Roche
QIAGEN
EntroGen
Amoy Diagnostics
ACCB Biotech
PD-L1 and PIK3CA Testing segment by Type
PD-L1 Testing
PIK3CA Testing
PD-L1 and PIK3CA Testing segment by Application
Hospital
Diagnostic Center
Others
PD-L1 and PIK3CA Testing segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 and PIK3CA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 and PIK3CA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 and PIK3CA Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of PD-L1 and PIK3CA Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of PD-L1 and PIK3CA Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 and PIK3CA Testing revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 PD-L1 and PIK3CA Testing Market by Type
1.2.1 Global PD-L1 and PIK3CA Testing Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 PD-L1 Testing
1.2.3 PIK3CA Testing
1.3 PD-L1 and PIK3CA Testing Market by Application
1.3.1 Global PD-L1 and PIK3CA Testing Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PD-L1 and PIK3CA Testing Market Dynamics
2.1 PD-L1 and PIK3CA Testing Industry Trends
2.2 PD-L1 and PIK3CA Testing Industry Drivers
2.3 PD-L1 and PIK3CA Testing Industry Opportunities and Challenges
2.4 PD-L1 and PIK3CA Testing Industry Restraints
3 Global Growth Perspective
3.1 Global PD-L1 and PIK3CA Testing Market Perspective (2019-2030)
3.2 Global PD-L1 and PIK3CA Testing Growth Trends by Region
3.2.1 Global PD-L1 and PIK3CA Testing Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global PD-L1 and PIK3CA Testing Market Size by Region (2019-2024)
3.2.3 Global PD-L1 and PIK3CA Testing Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global PD-L1 and PIK3CA Testing Revenue by Players
4.1.1 Global PD-L1 and PIK3CA Testing Revenue by Players (2019-2024)
4.1.2 Global PD-L1 and PIK3CA Testing Revenue Market Share by Players (2019-2024)
4.1.3 Global PD-L1 and PIK3CA Testing Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global PD-L1 and PIK3CA Testing Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global PD-L1 and PIK3CA Testing Key Players Headquarters & Area Served
4.4 Global PD-L1 and PIK3CA Testing Players, Product Type & Application
4.5 Global PD-L1 and PIK3CA Testing Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global PD-L1 and PIK3CA Testing Market CR5 and HHI
4.6.2 Global Top 5 and 10 PD-L1 and PIK3CA Testing Players Market Share by Revenue in 2023
4.6.3 2023 PD-L1 and PIK3CA Testing Tier 1, Tier 2, and Tier 3
5 PD-L1 and PIK3CA Testing Market Size by Type
5.1 Global PD-L1 and PIK3CA Testing Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global PD-L1 and PIK3CA Testing Revenue by Type (2019-2030)
5.3 Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2019-2030)
6 PD-L1 and PIK3CA Testing Market Size by Application
6.1 Global PD-L1 and PIK3CA Testing Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global PD-L1 and PIK3CA Testing Revenue by Application (2019-2030)
6.3 Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Agilent Technologies
7.1.1 Agilent Technologies Comapny Information
7.1.2 Agilent Technologies Business Overview
7.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Revenue and Gross Margin (2019-2024)
7.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio
7.1.5 Agilent Technologies Recent Developments
7.2 Roche
7.2.1 Roche Comapny Information
7.2.2 Roche Business Overview
7.2.3 Roche PD-L1 and PIK3CA Testing Revenue and Gross Margin (2019-2024)
7.2.4 Roche PD-L1 and PIK3CA Testing Product Portfolio
7.2.5 Roche Recent Developments
7.3 QIAGEN
7.3.1 QIAGEN Comapny Information
7.3.2 QIAGEN Business Overview
7.3.3 QIAGEN PD-L1 and PIK3CA Testing Revenue and Gross Margin (2019-2024)
7.3.4 QIAGEN PD-L1 and PIK3CA Testing Product Portfolio
7.3.5 QIAGEN Recent Developments
7.4 EntroGen
7.4.1 EntroGen Comapny Information
7.4.2 EntroGen Business Overview
7.4.3 EntroGen PD-L1 and PIK3CA Testing Revenue and Gross Margin (2019-2024)
7.4.4 EntroGen PD-L1 and PIK3CA Testing Product Portfolio
7.4.5 EntroGen Recent Developments
7.5 Amoy Diagnostics
7.5.1 Amoy Diagnostics Comapny Information
7.5.2 Amoy Diagnostics Business Overview
7.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue and Gross Margin (2019-2024)
7.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio
7.5.5 Amoy Diagnostics Recent Developments
7.6 ACCB Biotech
7.6.1 ACCB Biotech Comapny Information
7.6.2 ACCB Biotech Business Overview
7.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Revenue and Gross Margin (2019-2024)
7.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio
7.6.5 ACCB Biotech Recent Developments
8 North America
8.1 North America PD-L1 and PIK3CA Testing Revenue (2019-2030)
8.2 North America PD-L1 and PIK3CA Testing Revenue by Type (2019-2030)
8.2.1 North America PD-L1 and PIK3CA Testing Revenue by Type (2019-2024)
8.2.2 North America PD-L1 and PIK3CA Testing Revenue by Type (2025-2030)
8.3 North America PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
8.4 North America PD-L1 and PIK3CA Testing Revenue by Application (2019-2030)
8.4.1 North America PD-L1 and PIK3CA Testing Revenue by Application (2019-2024)
8.4.2 North America PD-L1 and PIK3CA Testing Revenue by Application (2025-2030)
8.5 North America PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
8.6 North America PD-L1 and PIK3CA Testing Revenue by Country
8.6.1 North America PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America PD-L1 and PIK3CA Testing Revenue by Country (2019-2024)
8.6.3 North America PD-L1 and PIK3CA Testing Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe PD-L1 and PIK3CA Testing Revenue (2019-2030)
9.2 Europe PD-L1 and PIK3CA Testing Revenue by Type (2019-2030)
9.2.1 Europe PD-L1 and PIK3CA Testing Revenue by Type (2019-2024)
9.2.2 Europe PD-L1 and PIK3CA Testing Revenue by Type (2025-2030)
9.3 Europe PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
9.4 Europe PD-L1 and PIK3CA Testing Revenue by Application (2019-2030)
9.4.1 Europe PD-L1 and PIK3CA Testing Revenue by Application (2019-2024)
9.4.2 Europe PD-L1 and PIK3CA Testing Revenue by Application (2025-2030)
9.5 Europe PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
9.6 Europe PD-L1 and PIK3CA Testing Revenue by Country
9.6.1 Europe PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe PD-L1 and PIK3CA Testing Revenue by Country (2019-2024)
9.6.3 Europe PD-L1 and PIK3CA Testing Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China PD-L1 and PIK3CA Testing Revenue (2019-2030)
10.2 China PD-L1 and PIK3CA Testing Revenue by Type (2019-2030)
10.2.1 China PD-L1 and PIK3CA Testing Revenue by Type (2019-2024)
10.2.2 China PD-L1 and PIK3CA Testing Revenue by Type (2025-2030)
10.3 China PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
10.4 China PD-L1 and PIK3CA Testing Revenue by Application (2019-2030)
10.4.1 China PD-L1 and PIK3CA Testing Revenue by Application (2019-2024)
10.4.2 China PD-L1 and PIK3CA Testing Revenue by Application (2025-2030)
10.5 China PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia PD-L1 and PIK3CA Testing Revenue (2019-2030)
11.2 Asia PD-L1 and PIK3CA Testing Revenue by Type (2019-2030)
11.2.1 Asia PD-L1 and PIK3CA Testing Revenue by Type (2019-2024)
11.2.2 Asia PD-L1 and PIK3CA Testing Revenue by Type (2025-2030)
11.3 Asia PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
11.4 Asia PD-L1 and PIK3CA Testing Revenue by Application (2019-2030)
11.4.1 Asia PD-L1 and PIK3CA Testing Revenue by Application (2019-2024)
11.4.2 Asia PD-L1 and PIK3CA Testing Revenue by Application (2025-2030)
11.5 Asia PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
11.6 Asia PD-L1 and PIK3CA Testing Revenue by Country
11.6.1 Asia PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia PD-L1 and PIK3CA Testing Revenue by Country (2019-2024)
11.6.3 Asia PD-L1 and PIK3CA Testing Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA PD-L1 and PIK3CA Testing Revenue (2019-2030)
12.2 MEALA PD-L1 and PIK3CA Testing Revenue by Type (2019-2030)
12.2.1 MEALA PD-L1 and PIK3CA Testing Revenue by Type (2019-2024)
12.2.2 MEALA PD-L1 and PIK3CA Testing Revenue by Type (2025-2030)
12.3 MEALA PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
12.4 MEALA PD-L1 and PIK3CA Testing Revenue by Application (2019-2030)
12.4.1 MEALA PD-L1 and PIK3CA Testing Revenue by Application (2019-2024)
12.4.2 MEALA PD-L1 and PIK3CA Testing Revenue by Application (2025-2030)
12.5 MEALA PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
12.6 MEALA PD-L1 and PIK3CA Testing Revenue by Country
12.6.1 MEALA PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA PD-L1 and PIK3CA Testing Revenue by Country (2019-2024)
12.6.3 MEALA PD-L1 and PIK3CA Testing Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. PD-L1 Testing Major Manufacturers
Table 2. PIK3CA Testing Major Manufacturers
Table 3. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 4. Hospital Major Manufacturers
Table 5. Diagnostic Center Major Manufacturers
Table 6. Others Major Manufacturers
Table 7. PD-L1 and PIK3CA Testing Industry Trends
Table 8. PD-L1 and PIK3CA Testing Industry Drivers
Table 9. PD-L1 and PIK3CA Testing Industry Opportunities and Challenges
Table 10. PD-L1 and PIK3CA Testing Industry Restraints
Table 11. Global PD-L1 and PIK3CA Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global PD-L1 and PIK3CA Testing Market Size by Region (2019-2024) & (US$ Million)
Table 13. Global PD-L1 and PIK3CA Testing Market Share by Region (2019-2024)
Table 14. Global PD-L1 and PIK3CA Testing Market Size by Region (2025-2030) & (US$ Million)
Table 15. Global PD-L1 and PIK3CA Testing Market Share by Region (2025-2030)
Table 16. Global PD-L1 and PIK3CA Testing Revenue by Players (US$ Million) & (2019-2024)
Table 17. Global PD-L1 and PIK3CA Testing Revenue Market Share by Players (2019-2024)
Table 18. Global PD-L1 and PIK3CA Testing Key Players Ranking, 2022 VS 2023 VS 2024
Table 19. Global PD-L1 and PIK3CA Testing Key Players Headquarters & Area Served
Table 20. Global PD-L1 and PIK3CA Testing Players, Product Type & Application
Table 21. Global PD-L1 and PIK3CA Testing Players Commercialization Time
Table 22. Global Players Market Concentration Ratio (CR5 and HHI)
Table 23. Global PD-L1 and PIK3CA Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 24. Global PD-L1 and PIK3CA Testing Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 25. Global PD-L1 and PIK3CA Testing Revenue by Type (2019-2024) & (US$ Million)
Table 26. Global PD-L1 and PIK3CA Testing Revenue by Type (2025-2030) & (US$ Million)
Table 27. Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 28. Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 29. Global PD-L1 and PIK3CA Testing Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global PD-L1 and PIK3CA Testing Revenue by Application (2019-2024) & (US$ Million)
Table 31. Global PD-L1 and PIK3CA Testing Revenue by Application (2025-2030) & (US$ Million)
Table 32. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 33. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 34. Agilent Technologies Company Information
Table 35. Agilent Technologies Business Overview
Table 36. Agilent Technologies PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 37. Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio
Table 38. Agilent Technologies Recent Development
Table 39. Roche Company Information
Table 40. Roche Business Overview
Table 41. Roche PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 42. Roche PD-L1 and PIK3CA Testing Product Portfolio
Table 43. Roche Recent Development
Table 44. QIAGEN Company Information
Table 45. QIAGEN Business Overview
Table 46. QIAGEN PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 47. QIAGEN PD-L1 and PIK3CA Testing Product Portfolio
Table 48. QIAGEN Recent Development
Table 49. EntroGen Company Information
Table 50. EntroGen Business Overview
Table 51. EntroGen PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 52. EntroGen PD-L1 and PIK3CA Testing Product Portfolio
Table 53. EntroGen Recent Development
Table 54. Amoy Diagnostics Company Information
Table 55. Amoy Diagnostics Business Overview
Table 56. Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 57. Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio
Table 58. Amoy Diagnostics Recent Development
Table 59. ACCB Biotech Company Information
Table 60. ACCB Biotech Business Overview
Table 61. ACCB Biotech PD-L1 and PIK3CA Testing Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 62. ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio
Table 63. ACCB Biotech Recent Development
Table 64. North America PD-L1 and PIK3CA Testing Revenue by Type (2019-2024) & (US$ Million)
Table 65. North America PD-L1 and PIK3CA Testing Revenue by Application (2019-2024) & (US$ Million)
Table 66. North America PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 67. North America PD-L1 and PIK3CA Testing Revenue by Country (2019-2024) & (US$ Million)
Table 68. North America PD-L1 and PIK3CA Testing Revenue by Country (2025-2030) & (US$ Million)
Table 69. Europe PD-L1 and PIK3CA Testing Revenue by Type (2019-2024) & (US$ Million)
Table 70. Europe PD-L1 and PIK3CA Testing Revenue by Application (2019-2024) & (US$ Million)
Table 71. Europe PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 72. Europe PD-L1 and PIK3CA Testing Revenue by Country (2019-2024) & (US$ Million)
Table 73. Europe PD-L1 and PIK3CA Testing Revenue by Country (2025-2030) & (US$ Million)
Table 74. China PD-L1 and PIK3CA Testing Revenue by Type (2019-2024) & (US$ Million)
Table 75. China PD-L1 and PIK3CA Testing Revenue by Application (2019-2024) & (US$ Million)
Table 76. Asia PD-L1 and PIK3CA Testing Revenue by Type (2019-2024) & (US$ Million)
Table 77. Asia PD-L1 and PIK3CA Testing Revenue by Application (2019-2024) & (US$ Million)
Table 78. Asia PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 79. Asia PD-L1 and PIK3CA Testing Revenue by Country (2019-2024) & (US$ Million)
Table 80. Asia PD-L1 and PIK3CA Testing Revenue by Country (2025-2030) & (US$ Million)
Table 81. MEALA PD-L1 and PIK3CA Testing Revenue by Type (2019-2024) & (US$ Million)
Table 82. MEALA PD-L1 and PIK3CA Testing Revenue by Application (2019-2024) & (US$ Million)
Table 83. MEALA PD-L1 and PIK3CA Testing Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 84. MEALA PD-L1 and PIK3CA Testing Revenue by Country (2019-2024) & (US$ Million)
Table 85. MEALA PD-L1 and PIK3CA Testing Revenue by Country (2025-2030) & (US$ Million)
Table 86. Research Programs/Design for This Report
Table 87. Authors List of This Report
Table 88. Secondary Sources
Table 89. Primary Sources
List of Figures
Figure 1. PD-L1 and PIK3CA Testing Product Picture
Figure 2. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global PD-L1 and PIK3CA Testing Market Size Share 2019 VS 2023 VS 2030
Figure 4. PD-L1 Testing Picture
Figure 5. PIK3CA Testing Picture
Figure 6. Global PD-L1 and PIK3CA Testing Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global PD-L1 and PIK3CA Testing Market Size Share 2019 VS 2023 VS 2030
Figure 8. Hospital Picture
Figure 9. Diagnostic Center Picture
Figure 10. Others Picture
Figure 11. Global PD-L1 and PIK3CA Testing Market Size (US$ Million) & (2019-2030)
Figure 12. Global PD-L1 and PIK3CA Testing Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global PD-L1 and PIK3CA Testing Market Share by Region: 2019 VS 2023 VS 2030
Figure 14. Global PD-L1 and PIK3CA Testing Players Revenue Share Top 10 and Top 5 in 2023
Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 16. Global PD-L1 and PIK3CA Testing Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 17. Global PD-L1 and PIK3CA Testing Revenue Market Share 2019 VS 2023 VS 2030
Figure 18. Global PD-L1 and PIK3CA Testing Revenue Market Share by Type (2019-2030)
Figure 19. Global PD-L1 and PIK3CA Testing Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 20. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 21. Global PD-L1 and PIK3CA Testing Revenue Market Share by Application (2019-2030)
Figure 22. North America PD-L1 and PIK3CA Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America PD-L1 and PIK3CA Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 24. North America PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
Figure 25. North America PD-L1 and PIK3CA Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 26. North America PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
Figure 27. North America PD-L1 and PIK3CA Testing Revenue Share by Country (2019-2030)
Figure 28. United States PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 29. Canada PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 30. Europe PD-L1 and PIK3CA Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe PD-L1 and PIK3CA Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 32. Europe PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
Figure 33. Europe PD-L1 and PIK3CA Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 34. Europe PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
Figure 35. Europe PD-L1 and PIK3CA Testing Revenue Share by Country (2019-2030)
Figure 36. Germany PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 37. France PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 38. U.K. PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. Italy PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. Russia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Nordic Countries PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. China PD-L1 and PIK3CA Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 43. China PD-L1 and PIK3CA Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 44. China PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
Figure 45. China PD-L1 and PIK3CA Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 46. China PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
Figure 47. Asia PD-L1 and PIK3CA Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 48. Asia PD-L1 and PIK3CA Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 49. Asia PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
Figure 50. Asia PD-L1 and PIK3CA Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 51. Asia PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
Figure 52. Asia PD-L1 and PIK3CA Testing Revenue Share by Country (2019-2030)
Figure 53. Japan PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 54. South Korea PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 55. India PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. Australia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. China Taiwan PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Southeast Asia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. MEALA PD-L1 and PIK3CA Testing Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 60. MEALA PD-L1 and PIK3CA Testing Revenue by Type (2025-2030) & (US$ Million)
Figure 61. MEALA PD-L1 and PIK3CA Testing Revenue Share by Type (2019-2030)
Figure 62. MEALA PD-L1 and PIK3CA Testing Revenue by Application (2025-2030) & (US$ Million)
Figure 63. MEALA PD-L1 and PIK3CA Testing Revenue Share by Application (2019-2030)
Figure 64. MEALA PD-L1 and PIK3CA Testing Revenue Share by Country (2019-2030)
Figure 65. Mexico PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 66. South Korea PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 67. Brazil PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. Israel PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Argentina PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Colombia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Turkey PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Saudi Arabia PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. UAE PD-L1 and PIK3CA Testing Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Years Considered
Figure 75. Research Process
Figure 76. Key Executives Interviewed
